金迪克2025年归属净利润亏损1.73亿元

Core Viewpoint - The company reported a significant increase in revenue but also a substantial net loss for the fiscal year 2025, indicating challenges in profitability despite growth in sales [1]. Group 1: Financial Performance - The company achieved an operating revenue of 113 million yuan, representing a year-on-year growth of 40.13% [1]. - The net profit attributable to shareholders was -17.3 million yuan, indicating an increase in losses compared to the previous year [1]. Group 2: Product Development and Regulatory Status - The company completed the enrollment of participants for the Phase III clinical trial of its quadrivalent influenza virus split vaccine for children and has finished the vaccination process [1]. - The application for market production of the trivalent influenza virus split vaccine has been accepted, with various regulatory checks completed, awaiting further review by the CDE [1]. Group 3: Inventory and Asset Management - Due to equipment failures and material discrepancies, the company decided not to sell certain in-process and finished products, adhering to a cautious approach [2]. - The quadrivalent influenza virus split vaccine has a shelf life of 12 months, and any unused vaccines at the end of the flu season must be disposed of according to legal requirements [2]. - The company has made provisions for asset impairment and inventory write-offs totaling approximately 41.9996 million yuan, based on market research and historical return rates [2].